Syndax Pharmaceuticals (SNDX) Liabilities and Shareholders Equity (2015 - 2026)

Syndax Pharmaceuticals' Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $472.7 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 26.23% year-over-year to $472.7 million; the TTM figure through Mar 2026 stood at $2.2 billion (down 5.2% YoY), while the FY2025 annual figure was $529.7 million, down 26.92% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $472.7 million, down from $529.7 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $724.8 million in Q4 2024, with the low at $359.7 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $476.9 million (2024), against an average of $503.0 million.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 54.5% in 2022, then retreated 26.92% in 2025.
• Syndax Pharmaceuticals' Liabilities and Shareholders Equity stood at $497.2 million in 2022, then increased by 23.26% to $612.9 million in 2023, then rose by 18.26% to $724.8 million in 2024, then declined by 26.92% to $529.7 million in 2025, then retreated by 10.77% to $472.7 million in 2026.
• Business Quant data shows SNDX's Liabilities and Shareholders Equity at $472.7 million in Q1 2026, $529.7 million in Q4 2025, and $551.8 million in Q3 2025.